A recent study suggested that a MUC1/CD3 BsAb (PLGA nanoparticle connected with an anti-MUC1 mAb and anti-CD3 mAb) conjugated CIK cell therapy showed encouraging clinical results in hepatocellular carcinoma patients when combined with anti-PD1 treatment [42]. The gene discussed is MUC1; the disease is hepatocellular carcinoma.